ESTRO 2024 - Abstract Book

S773

Clinical - CNS

ESTRO 2024

All these factors, as well as the evidence of residual disease on MRI (p .015), and VPTV57 Gy <96.4% (p .03), were correlated to worse PFS

Conclusion:

Our analysis confirmed the prognostic value of grading and mutational status of HGG. Interestingly, FET-PET parameters and an optimal coverage of target volume influenced OS and PFS. Further analysis are needed to validate the usefulness of FET PET parameters in the RT planning, in order to improve the clinical outcomes of pts with HGG

Keywords: FET-PET, glioma, radiotherapy

References:

Galldiks N, Langen KJ, Pope WB. From the clinician’s point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol. 2015;17(11):1434-1444. doi:10.1093/neuonc/nov118

Zaccagna F, Grist JT, Quartuccio N, et al. Imaging and treatment of brain tumors through molecular targeting: Recent clinical advances. Eur J Radiol. 2021;142:109842. doi:10.1016/j.ejrad.2021.109842

Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199-1208. doi:10.1093/neuonc/now058 Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540-557. doi:10.1007/s00259-018-4207-9

Alam IS, Arshad MA, Nguyen Q-D, Aboagye EO. Radiopharmaceuticals as probes to characterize tumour tissue. Eur J Nucl Med Mol Imaging. 2015;42(4):537-561. doi:10.1007/s00259-014-2984-3

Muthu M, Nordström A. Current Status and Future Prospects of Clinically Exploiting Cancer-specific Metabolism — Why Is Tumor Metabolism Not More Extensively Translated into Clinical Targets and Biomarkers? Int J Mol Sci. 2019;20(6):1385. doi:10.3390/ijms20061385

Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016;23(1):27-47. doi:10.1016/j.cmet.2015.12.006

Lopes C, Pereira C, Medeiros R. ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: From a Molecular Perspective to Clinical Translation. Cancers (Basel). 2021;13(2):203. doi:10.3390/cancers13020203

Li L, Wang Y, Li Y, Fang S, Jiang T. Role of molecular biomarkers in glioma resection: A systematic review. Chinese Neurosurg J. 2020;6(1):1-7. doi:10.1186/s41016-020-00198-x

Fuenfgeld B, Mächler P, Fischer DR, et al. Reference values of physiological 18F-FET uptake: Implications for brain tumor discrimination. PLoS One. 2020;15(4):1-16. doi:10.1371/journal.pone.0230618